Pfizer EVP granted 303,151 stock appreciation rights

Baum Andrew reported acquisition or exercise transactions in this Form 4 filing.

Accepted by SEC EDGAR 03/05/2026 - 05:26 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Baum Andrew reported acquisition or exercise transactions in this Form 4 filing.

Pfizer Inc. Executive Vice President Andrew Baum reported an equity compensation grant in the form of 303,151 stock appreciation rights. These stock appreciation rights are subject to vesting requirements and will be settled in shares of Pfizer common stock on the fifth anniversary of the grant date.

Insider Trade Summary

Grant/Award: 303,151 shares

Grant/Award 1 txn

Insider Baum Andrew

Role Executive Vice President

Type	Security	Shares	Price	Value
Grant/Award	Stock Appreciation Rights	303,151	$0.00	$0.00

Holdings After Transaction: Stock Appreciation Rights — 303,151 contracts (Direct)

Holdings Before and After: Stock Appreciation Rights, 0 to 303,151 contracts (Direct)

Footnotes (1)

1. F1. The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Pfizer (PFE) executive Andrew Baum report in this Form 4 filing?

Andrew Baum reported receiving 303,151 stock appreciation rights as equity compensation. These derivative awards provide value based on Pfizer’s share price and will be settled in Pfizer common stock after specified vesting and timing conditions are met.

How many stock appreciation rights did Andrew Baum receive from Pfizer (PFE)?

Andrew Baum received 303,151 stock appreciation rights. Each right represents a derivative award tied to Pfizer common stock, granted at no cash cost per unit and subject to vesting before being settled in actual Pfizer shares at a future date.

When will Andrew Baum’s Pfizer (PFE) stock appreciation rights be settled?

The stock appreciation rights will be settled in Pfizer common stock on the fifth anniversary of the grant date. Settlement occurs only after vesting requirements are satisfied, meaning Baum receives shares several years after the original award is granted.

Are Andrew Baum’s stock appreciation rights in Pfizer (PFE) subject to vesting?

Yes, the stock appreciation rights are subject to vesting requirements. Baum must satisfy these conditions before receiving Pfizer common stock, and settlement will then occur on the fifth anniversary of the grant date, aligning with long-term incentive compensation practices.

Does Andrew Baum pay a purchase price for these Pfizer (PFE) stock appreciation rights?

The reported transaction price per stock appreciation right is zero. This indicates the award is part of compensation rather than an open-market purchase, with value realized later through settlement in Pfizer common stock after vesting and the five-year holding period.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Baum Andrew

(Last) (First) (Middle)

66 HUDSON BOULEVARD EAST

ATTN: CORPORATE SECRETARY

(Street)

NEW YORK NY 10001-2192

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PFIZER INC [ PFE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Vice President

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Appreciation Rights	$26.58	03/03/2026		A		303,151		03/03/2031(1)	03/03/2031(1)	Common Stock	303,151	$0.0000	303,151	D

Explanation of Responses:

1. The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

	/s/Shanice A. Reid, by power of atty, for Andrew Baum	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.